A Study of Imvotamab in Severe Systemic Lupus Erythematosus

Summary

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies. Participants will be given imvotamab through a vein (i.e., intravenously).

Timeline

Start

2023-08-15

Primary completion

2025-01-27

Completion

2025-01-27

Outcome

Outcome not reported

Stopped: “Company Decision.”

Drugs

Indications